To hear about similar clinical trials, please enter your email below
Trial Title:
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients (HKCH)
NCT ID:
NCT06505057
Condition:
Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
Description:
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
Arm group label:
ovarian tissue freezing and subsequent auto-transplantation after thawing
Summary:
Ovarian tissue freezing is an ideal option for these patients as it can be performed
immediately and does not need any time for ovarian stimulation. We hope we can develop
this service in our locality to allow more young female cancer patients to have their
fertility preserved.
Detailed description:
To date, transplantation of cryopreserved ovarian tissue has resulted in births of at
least 130 children but data on transplantation of ovarian tissue removed before puberty
are scarce.
During ovarian tissue cryopreservation (OTC), it is possible to freeze isolated oocytes.
In 2003, Revel et al described for the first time oocyte isolation in children younger
than 12 years with seven, eight and seven oocytes isolated from the ovarian cortex of
patients aged 5, 8 and 10 years, respectively.
At this moment, financial constraint is another great hindrance to fertility preservation
in Hong Kong as the procedure is not cheap. Cryopreservation of gametes and embryos
involving assisted reproductive technology is expensive and the costs of fertility
preservation impose a great burden to these cancer patients on top of the great expenses
for their chemo- or radiotherapy. It is almost impossible for underprivileged families.
Young cancer patients may often need immediate gonadotoxic treatment for their cancer,
just like those with haematological cancers. In these patients, egg or embryo freezing is
not possible as it takes at least 8-12 days' time for ovarian stimulation. Ovarian tissue
freezing is an ideal option for these patients as it can be performed immediately and
does not need any time for ovarian stimulation. We hope we can develop this service in
our locality to allow more young female cancer patients to have their fertility
preserved.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia,
myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological
neoplasms and sarcoma, Paediatric bone marrow transplant patients
- Patients with any illness or who will undergo any type of treatment that may cause
irreversible damage to their fertility, such as extensive abdominal surgery, high
toxicity medication and treatments;
- Patients suffering from hormone-sensitive malignancies who will undergo medical
treatment, such as radiotherapy and chemotherapy that is liable to damage their
ovaries and deter them from conception in the future.
Exclusion Criteria:
Patients with no anticipated oncologic therapies Patients who are pregnant Children with
one ovary Children deemed high risk for perioperative complications Patients unable to
provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
-
Gender:
Female
Minimum age:
12 Years
Maximum age:
18 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Hong Kong Children's Hospital
Address:
City:
Hong Kong
Country:
Hong Kong
Status:
Recruiting
Contact:
Last name:
Elaine NG, MPhil
Phone:
35052745
Email:
elaineng@cuhk.edu.hk
Contact backup:
Last name:
Jacqueline Pui Wah CHUNG, MBBS
Phone:
35051537
Email:
acquelinechung@cuhk.edu.hk
Start date:
August 13, 2024
Completion date:
July 31, 2041
Lead sponsor:
Agency:
Chinese University of Hong Kong
Agency class:
Other
Source:
Chinese University of Hong Kong
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06505057
